Pazopanib

Pazopanib is an oral tyrosine kinase inhibitor (TKI) targeting multiple receptors involved in tumor growth and angiogenesis, including VEGFR, PDGFR, and c-KIT. It is primarily used in cancer therapy to slow or stop the progression of cancerous cells.

Indications

-Advanced renal cell carcinoma (RCC) -Soft tissue sarcoma (STS)

Dosage

-Recommended Dose for Adults: 800 mg once daily on an empty stomach (at least 1 hour before or 2 hours after a meal). -Dose adjustments may be necessary based on individual tolerance and hepatic function.

Contra-Indications

-Known hypersensitivity to Pazopanib or any of its components. -Severe hepatic impairment.

Special Precautions

-Monitor liver function tests before and during treatment. -Use with caution in patients with cardiovascular conditions, including hypertension or QT prolongation. -Avoid use in pregnant and lactating women unless essential. -Regular blood pressure monitoring is advised.

Side Effects

Common side effects may include: Fatigue Diarrhea -Hypertension -Nausea -Anorexia -Skin discoloration -Rare but serious side effects: -Hepatotoxicity -Cardiac dysfunction -Hemorrhagic events